To me, its' JBM Healthcare. On the surface, its' an unknown newly floated issue. However, underneath, it represents a powerpack of legacy trusted chinese healthcare brands that has went through thick & thin with chinese people. Brand value resides in consumer's trust in them & on this scale, JBM's brands is of the highest quality.
Revisiting Warren's quote at the beginning of this write up, JBM Healthcare has used its cashflow surpluses to eliminate debt (*yes, its a zero debt company); while returning shareholder value via a stock buyback program that ended up purchasing 10% of outstanding shares & an 8% dividend so far this year. That comes up to a total of +19% shareholder return in 2024 even with Hong Kong Exchange closed for the year. Speaking of minority shareholder interest. Cheers.
Modify on 2024-10-04 18:23
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
